Genfit is a biotechnology business based in the US. Genfit shares (GNFT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.31 – a decrease of 4.96% over the previous week. Genfit employs 169 staff and has a trailing 12-month revenue of around $80.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.31 |
|---|---|
| 52-week range | $3.08 - $6.42 |
| 50-day moving average | $5.30 |
| 200-day moving average | $4.32 |
| Wall St. target price | $9.73 |
| PE ratio | 11.5385 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.39 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.2629 from 2024-11-19
| 1 week (2024-11-14) | -6.00% |
|---|---|
| 1 month (2024-10-21) | -28.29% |
| 3 months (2024-08-21) | -3.16% |
| 6 months (2024-05-21) | 3.97% |
| 1 year (2023-11-21) | 33.63% |
|---|---|
| 2 years (2022-11-21) | 9.87% |
| 3 years (2021-11-19) | 21.42% |
| 5 years (2019-11-21) | 15.19 |
Valuing Genfit stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genfit's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genfit's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Genfit shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Genfit's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.9 million.
The EBITDA is a measure of a Genfit's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $80.5 million |
|---|---|
| Operating margin TTM | 51% |
| Gross profit TTM | $26.2 million |
| Return on assets TTM | 6.51% |
| Return on equity TTM | 25.91% |
| Profit margin | 27.68% |
| Book value | $1.96 |
| Market Capitalization | $227.2 million |
TTM: trailing 12 months
We're not expecting Genfit to pay a dividend over the next 12 months.
Over the last 12 months, Genfit's shares have ranged in value from as little as $3.08 up to $6.4229. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genfit's is 1.122. This would suggest that Genfit's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Genfit S. A. , a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.